BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

953 related articles for article (PubMed ID: 16030305)

  • 1. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
    Castle PE; Solomon D; Schiffman M; Wheeler CM
    J Natl Cancer Inst; 2005 Jul; 97(14):1066-71. PubMed ID: 16030304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
    Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
    J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.
    Castle PE; Shaber R; LaMere BJ; Kinney W; Fetterma B; Poitras N; Lorey T; Schiffman M; Dunne A; Ostolaza JM; McKinney S; Burk RD
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):946-53. PubMed ID: 21415357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
    Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
    J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
    Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
    Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection.
    Keller MJ; Burk RD; Xie X; Anastos K; Massad LS; Minkoff H; Xue X; D'Souza G; Watts DH; Levine AM; Castle PE; Colie C; Palefsky JM; Strickler HD
    JAMA; 2012 Jul; 308(4):362-9. PubMed ID: 22820789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.
    Castle PE; Lorincz AT; Scott DR; Sherman ME; Glass AG; Rush BB; Wacholder S; Burk RD; Manos MM; Schussler JE; Macomber P; Schiffman M
    J Clin Microbiol; 2003 Sep; 41(9):4022-30. PubMed ID: 12958220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
    Sand FL; Munk C; Frederiksen K; Junge J; Iftner T; Dehlendorff C; Kjaer SK
    Int J Cancer; 2019 Apr; 144(8):1975-1982. PubMed ID: 30246864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology.
    McIntyre-Seltman K; Castle PE; Guido R; Schiffman M; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1165-70. PubMed ID: 15894667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.
    Schiffman M; Vaughan LM; Raine-Bennett TR; Castle PE; Katki HA; Gage JC; Fetterman B; Befano B; Wentzensen N
    Gynecol Oncol; 2015 Sep; 138(3):573-8. PubMed ID: 26148763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Performance of APTIMA Human Papillomavirus (HPV) 16 18/45 mRNA Genotyping Testing for the Detection of Cervical Intraepithelial Neoplasia 3 (CIN3) or Cancer in a Select Group of Chinese Women.
    Guo YL; You K; Geng L; Qiao J
    Pathol Oncol Res; 2016 Jul; 22(3):549-54. PubMed ID: 26710763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.